New HIV vaccine shows promise in early human trial

NCT ID NCT04915768

Completed ⭐️ VACCINE ⭐️ Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tested a new HIV vaccine in 51 healthy adults to see if it is safe and triggers an immune response. The vaccine aims to train the body to produce special antibodies that can fight HIV. Researchers also tested different combinations of adjuvants (ingredients that boost the immune response) to find the best balance of effectiveness and side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV INFECTIONS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HIV infectious disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV INFECTIONS

Contacts and locations

Locations

Brigham and Women's CRS

Boston, Massachusetts, 02115, United States
The Hope Clinic of the Emory Vaccine Center CRS

Decatur, Georgia, 30030, United States
Vanderbilt Vaccine (VV) CRS

Nashville, Tennessee, 30030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.